Anthony Aemmer, APRN
Psychiatric/Mental Health · Jeffersonville, INNPI 1659974806
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.5% of the total across 619 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 23.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,014, 4.6 times the $651 reported in 2021. Among psychiatric/mental health clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 619 payments — averaging $15.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Teva Pharmaceuticals USA, Inc.$853
- Lundbeck LLC$753
- Neurocrine Biosciences, Inc.$664
- Alkermes, Inc.$631
- plus $3K from 16 others
What the payments were for
- Consulting fees$1151%
- Food & beverage$8,96897%
- Education$2072%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 225 | $2,151 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 83 | $1,504 |
| Teva Pharmaceuticals USA, Inc. | 46 | $853 |
| Lundbeck LLC | 50 | $753 |
| Neurocrine Biosciences, Inc. | 35 | $664 |
| Alkermes, Inc. | 34 | $631 |
| Otsuka America Pharmaceutical, Inc. | 36 | $604 |
| E.r. Squibb & Sons, L.L.C. | 17 | $428 |
| Johnson & Johnson | 20 | $376 |
| Axsome Therapeutics, Inc. | 17 | $265 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $212 |
| Indivior Inc. | 9 | $150 |
| Vanda Pharmaceuticals Inc. | 8 | $146 |
| Janssen Scientific Affairs, LLC | 1 | $115 |
| Sunovion Pharmaceuticals Inc. | 10 | $113 |
| Idorsia Pharmaceuticals US Inc | 7 | $108 |
| Supernus Pharmaceuticals, Inc. | 4 | $102 |
| Exact Sciences | 1 | $27 |
| Tris Pharma Inc | 1 | $24 |
| Eisai Inc. | 2 | $24 |
| Novo Nordisk | 1 | $22 |
| Noven Therapeutics, LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$619
- CAPLYTA$344
- COBENFY$250
- UZEDY$120
- INGREZZA$118
- SPRAVATO$115
- INVEGA TRINZA$102
- INVEGA SUSTENNA$102
How this compares
$9,290 in reported general payments places this provider in the 95th percentile of 729 psychiatric/mental health providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 55 | $144,181 |
| VraylarCariprazine Hcl | 101 | $138,367 |
| Austedo XrDeutetrabenazine | 17 | $78,112 |
| AristadaAripiprazole Lauroxil | 17 | $49,854 |
| CaplytaLumateperone Tosylate | 30 | $48,695 |
| RexultiBrexpiprazole | 30 | $43,064 |
| TrintellixVortioxetine Hydrobromide | 82 | $40,343 |
| Abilify MaintenaAripiprazole | 15 | $32,678 |
| Lurasidone Hcl | 27 | $11,044 |
| Aripiprazole | 86 | $9,258 |
| BelsomraSuvorexant | 14 | $8,747 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 62 | $8,293 |
| QuviviqDaridorexant Hcl | 13 | $6,319 |
| Ramelteon | 27 | $6,293 |
| Clozapine | 55 | $5,558 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $376 | $144,18155 claims |
| AbbVieVraylar | $2,151 | $138,367101 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $853 | $78,11217 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $604 | $75,74245 claims |
| Alkermes, Inc.Aristada | $631 | $49,85417 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,504 | $48,69530 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $212 | $40,34382 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $108 | $6,31913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 729 psychiatric/mental health providers in Indiana.
Other psychiatric/mental health in Jeffersonville
- Paul DuncanJeffersonville$46K
- Matthew CulbrethJeffersonville$7K
- Brooke KempfTerre Haute$1.1M
- Gerald LewisMerrillville$336K
- Lauren LutzColumbus$320K
- Sonya RuedlingerIndianapolis$134K
- Trina GreenwaldMarion$107K
- Morgan StamperConnersville$42K
- Jennifer JimenezUnion Mills$37K
- Savannah MullinsClarksville$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.